82Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al: International Agency for Research on Cancer (IARC). GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11. Lyon, IARC, 2017. globocan.iarc.fr.
83Hamilton EJ, Gianatti E, Strauss BJ, Wentworth J, Lim-Joon D, Bolton D, et al: Increase in visceral and subcutaneous abdominal fat in men with prostate cancer treated with androgen deprivation therapy. Clin Endocrinol (Oxf) 2011;74:377–383.
84Smith MR, Finkelstein JS, McGovern FJ, Zietman AL, Fallon MA, Schoenfeld DA, et al: Changes in body composition during androgen deprivation therapy for prostate cancer. J Clin Endocrinol Metab 2002;87:599–603.
85Owen PJ, Daly RM, Livingston PM, Fraser SF: Lifestyle guidelines for managing adverse effects on bone health and body composition in men treated with androgen deprivation therapy for prostate cancer: an update. Prostate Cancer Prostatic Dis 2017;20:137–145.
86Smith MR, Lee H, McGovern F, Fallon MA, Goode M, Zietman AL, et al: Metabolic changes during gonadotropin-releasing hormone agonist therapy for prostate cancer: differences from the classic metabolic syndrome. Cancer 2008;112:2188–2194.
87Dohle GR, Arver S, Bettocchi C, Jones TH, Kliesch S, Punab M: Guidelines on male hypogonadism. Eur Assoc Urol 2015. https://uroweb.org/guideline/male-hypogonadism/ (accessed: April 18, 2019).
88Elbers JM, Asscheman H, Seidell JC, Gooren LJ: Effects of sex steroid hormones on regional fat depots as assessed by magnetic resonance imaging in transsexuals. Am J Physiol 1999;276(2 Pt 1):E317–E325.
89Gooren LJ: Management of female-to-male transgender persons: medical and surgical management, life expectancy. Curr Opin Endocrinol Diabetes Obes 2014;21:233–238.
90Traish AM, Gooren LJ: Safety of physiological testosterone therapy in women: lessons from female-to-male transsexuals (FMT) treated with pharmacological testosterone therapy. J Sex Med 2010;7:3758–3764.
91Velho I, Fighera TM, Ziegelmann PK, Spritzer PM: Effects of testosterone therapy on BMI, blood pressure, and laboratory profile of transgender men: a systematic review. Andrology 2017;5:881–888.
92Conway G, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Franks S, Gambineri A, et al: The polycystic ovary syndrome: a position statement from the European Society of Endocrinology. Eur J Endocrinol 2014;171:P1–P29.
93Moghetti P, Tosi F, Bonin C, Di Sarra D, Fiers T, Kaufman JM, et al: Divergences in insulin resistance between the different phenotypes of the polycystic ovary syndrome. J Clin Endocrinol Metab 2013;98:E628–E637.
94Pasquali R, Zanotti L, Fanelli F, Mezzullo M, Fazzini A, Morselli Labate AM, et al: Defining hyperandrogenism in women with polycystic ovary syndrome: a challenging perspective. J Clin Endocrinol Metab 2016;101:2013–2022.
95Poddar M, Chetty Y, Chetty VT: How does obesity affect the endocrine system? A narrative review. Clin Obes 2017;7:136–144.
96Escobar-Morreale HF, San Millán JL: Abdominal adiposity and the polycystic ovary syndrome. Trends Endocrinol Metab 2007;18:266–272.
97Bhasin S, Storer TW, Berman N, Callegari C, Clevenger B, Phillips J, et al: The effects of supraphysiologic doses of testosterone on muscle size and strength in normal men. N Engl J Med 1996;335:1–7.
98Birzniece V: Doping in sport: effects, harm and misconceptions. Intern Med J 2015;45:239–248.
99Kirchengast S: Gender differences in body composition from childhood to old age: an evolutionary point of view. J Life Sci 2010;2:1–10.
100Larsson I, Lissner L, Samuelson G, Fors H, Lantz H, Näslund I, et al: Body composition through adult life: Swedish reference data on body composition. Eur J Clin Nutr 2015;69:837–842.
101Vandewalle S, Taes Y, Fiers T, Toye K, Van Caenegem E, Roggen I, et al: Associations of sex steroids with bone maturation, bone mineral density, bone geometry, and body composition: a cross-sectional study in healthy male adolescents. J Clin Endocrinol Metab 2014;99:E1272–E1282.
102Vermeulen A, Kaufman JM, Giagulli VA: Influence of some biological indexes on sex hormone-binding globulin and androgen levels in aging or obese males. J Clin Endocrinol Metab 1996;81:1821–186.
Vito Angelo Giagulli
Outclinic Patients for Endocrinology and Metabolic Diseases, Conversano Hospital
Via De Amicis 30
IT–70014 Conversano (Ba) (Italy)
E-Mail [email protected]
Конец ознакомительного фрагмента.
Текст предоставлен ООО «ЛитРес».
Прочитайте эту книгу целиком, купив полную легальную версию на ЛитРес.
Безопасно оплатить книгу можно банковской картой Visa, MasterCard, Maestro, со счета мобильного телефона, с платежного терминала, в салоне МТС или Связной, через PayPal, WebMoney, Яндекс.Деньги, QIWI Кошелек, бонусными картами или другим удобным Вам способом.